Nasdaq · Healthcare
GILEAD SCIENCES, INC. (GILD)
As-reported financials and recent SEC filings for GILEAD SCIENCES, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$29.44B
Net income
$8.51B
Net margin
28.9%
Diluted EPS
$6.78
ROE
37.6%
P/E (TTM)
17.1×
Market cap
$155.93B
Debt / equity
1.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B |
| Gross profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B |
| Net income | $8.51B | $480.0M | $5.67B | $4.59B | $6.22B |
| Diluted EPS | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-02
View on EDGAR →1442026-06-01
View on EDGAR →42026-05-27
View on EDGAR →SCHEDULE 13D/A2026-05-27
View on EDGAR →8-K2026-05-20
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →424B52026-05-18
View on EDGAR →Go deeper on GILD
Search GILEAD SCIENCES, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.